Search company, investor...

Sierra Neuropharmaceuticals

Founded Year



Dead | Dead

Total Raised


About Sierra Neuropharmaceuticals

SierraNeuro develops and commercializes therapeutic products for medically refractory patients with CNS diseases. Sierra has addressed the problems these patients face by reformulating highly effective oral medications for placement into an implantable pump, for direct administration into the fluid around the brain, to treat CNS diseases including Epilepsy, Schizophrenia, Bipolar Disorder, Anxiety Disorders and Major Depression.

Headquarters Location

12635 East Montview Boulevard Suite 131

Aurora, Colorado, 80010,

United States


Missing: Sierra Neuropharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sierra Neuropharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Sierra Neuropharmaceuticals Frequently Asked Questions (FAQ)

  • When was Sierra Neuropharmaceuticals founded?

    Sierra Neuropharmaceuticals was founded in 2005.

  • Where is Sierra Neuropharmaceuticals's headquarters?

    Sierra Neuropharmaceuticals's headquarters is located at 12635 East Montview Boulevard, Aurora.

  • What is Sierra Neuropharmaceuticals's latest funding round?

    Sierra Neuropharmaceuticals's latest funding round is Dead.

  • How much did Sierra Neuropharmaceuticals raise?

    Sierra Neuropharmaceuticals raised a total of $21.5M.

  • Who are the investors of Sierra Neuropharmaceuticals?

    Investors of Sierra Neuropharmaceuticals include Sequel Venture Partners, GC&H Investments, Morgenthaler Ventures, High Country Venture and Colorado Fund.

  • Who are Sierra Neuropharmaceuticals's competitors?

    Competitors of Sierra Neuropharmaceuticals include Aphios, Array Biopharma, Keryx Biopharmaceuticals, Ocera Therapeutics, ActoGeniX and 11 more.

Compare Sierra Neuropharmaceuticals to Competitors


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.


BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.